J&J, Idorsia plan filings for aprocitentan data in resistant hypertension

People whose blood pressure remains stubbornly high despite current drug treatment and are at increased risk of complications such as kidney disease and stroke could have another treatment option in future, developed by Johnson & Johnson and Idorsia.